Published in Gene Therapy Weekly, December 23rd, 2004
Through the financing the University of Chicago, MEDIAN's scientific partner, became a company shareholder.
"We are very happy to enjoy the trust of such prestigious financial partners in our vision, our technology and our team. We are also very proud that the University of Chicago, the acknowledged leader in CAD activity in the world, has acquired a stake in our capital," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly